Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal Nalmefene in Healthy Volunteers
NCT03129347Phase 1Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Jun 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nalmefene in opioid use disorder (OUD) (4 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Pharmacokinetic parameters of nalmefene at 17 days. Started Jun 2017; status: completed.
02
Drugs
nalmefene
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03129347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129347.